Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

2 articles matching "runx1-fpd"

GrantNIH REPORTERMay 11

New NIH Grant: The RUNX1 Research Program 10th Annual Scientific Conference and Patient Meeting — $10K at Unknown Institution

The National Institutes of Health is funding a conference bringing together researchers, doctors, and patients with RUNX1-FPD, a rare blood disorder where people have a high risk of developing blood cancers. The conference aims to help experts share what they know and work together to improve care and research for this condition.

WHY IT MATTERSThis conference creates a dedicated space for RUNX1-FPD patients and families to connect with leading researchers and clinicians studying their specific condition, which is critical since many people with this disorder face a 35-50% lifetime risk of developing blood cancer.
Good to knowRUNX1 familial platelet disorder with predisposition to hematologic malignanciesRUNX1-FPDFPDMM
Clinical trialCLINICALTRIALSMar 27

Trial Now Recruiting: Longitudinal Studies of Patient With FPDMM (NCT03854318)

Researchers are looking for 1,000 people of any age who have a rare blood disorder called FPDMM, which is caused by a change in the RUNX1 gene. People with this condition may bleed easily and for longer than normal when injured. This study will help doctors better understand the disease, diagnose it more accurately, and find better ways to treat it.

WHY IT MATTERSThis is an active recruiting trial sponsored by the National Human Genome Research Institute seeking 1,000 participants with RUNX1-variant FPDMM — participation could directly advance understanding of diagnosis and treatment for this rare inherited bleeding disorder.
You can act on thisFPDMM

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases